RxDoctor Payments Data

Cassandra Smith, DPM

Foot & Ankle Surgery · Sandusky, OHNPI 1811164692

Payments from drug & device makers

$4,150in general payments, 2019–2025

Across 97 payments — averaging $42.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CDC Medical LLC$2K
  • Organogenesis Inc.$557
  • Smith+Nephew$255
  • Averitas Pharma Inc.$226
  • ANI Pharmaceuticals, Inc.$190
  • Mimedx Group, Inc.$168
  • plus $1K from 26 others

What the payments were for

  • Travel & lodging$672%
  • Food & beverage$2,56762%
  • Education$1,51637%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,150 in reported general payments places this provider in the 55th percentile of 429 foot & ankle surgery providers in Ohio.

See all foot & ankle surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$266,574
Medicare patients
546
Services billed
23,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser27$95,934
JubliaEfinaconazole15$26,669
Pregabalin39$1,432
Colchicine15$1,421
Ammonium Lactate30$868
Ciclopirox34$829
Terbinafine Hcl28$686
Etodolac ErEtodolac11$304
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$274
Doxycycline Hyclate35$269
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen39$255
Gabapentin38$248
Prednisone79$245
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$146
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GRT US Holding, Inc.Qutenza$21$95,93427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 429 foot & ankle surgery providers in Ohio.

Other foot & ankle surgery in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →